ar101 - search results

If you're not happy with the results, please do another search
AAFA Press Release Regarding ICER Review

Asthma and Allergy Foundation of America Elevates Patient Voice in ICER Review of New...

Affirms Burden of Food Allergies on Families, Patients, and Caregivers.
FARE-ACAAI-AAN Statement

Joint Statement on Peanut Allergy Therapy Review

Organizations representing patients and allergists urge ICER to adopt a more patient-driven approach to assessing immunotherapies for peanut allergy.
Anxious Teen

Study: Over Half of Teens with Peanut Allergy Visited the ER, Over One-Third Required...

4 in 10 Teens believe they have a great or very great chance or certainty of dying from accidental exposure.
OIT

Leading Allergists, Researchers and Food Allergy Advocates to Discuss State of ‘Food Oral Immunotherapy...

The summit intends to address the risks and benefits of OIT, OIT implementation in practice and the gaps in knowledge about OIT to enable physicians to have a better understanding of this therapy and to help patients make fully-informed choices about treatment options.
Infighting

OIT is a Therapy, Not an Ideology

The decisions we all face as patients and caretakers depend on the individual, their allergies, their lifestyles and myriad other factors.
Eggs

Aimmune to Begin Phase 2 Trials of Egg Allergy OIT Candidate

AR201 for Egg Allergy Phase 2 Initiation Planned for 2019.
Peanuts

Non-Profit Institute to Review Benefits of Commercial, Private Practice Immunotherapies for Peanut Allergy

An independent review of the value, costs and effectiveness of Viaskin Peanut, AR101, and private practice peanut OIT.
AR101

New Treatment to Protect People with Peanut Allergies Ready for FDA Review

"Two thirds of the people in the study were able to tolerate the equivalent of two peanuts per day after 9 to 12 months of treatment."
Stressed Boy

European Study Shows Significant Psychosocial Burden Associated with Peanut Allergy

Data discussed at EAACI 2018 reveal uncertainty, bullying and high levels of anxiety around food.
Paliforzia (AR101)

Peanut OIT Phase 3 Trial Results Show Therapy Effective for Ages 4-55

Aimmune plans to submit a Biologics License Application for AR101 to the FDA by the end of 2018.